References
- Bailey I, Gibson GG, Plant K, et al. (2011). A PXR-mediated negative feedback loop attenuates the expression of CYP3A in response to the PXR agonist pregnenalone-16α-carbonitrile. PLoS One 6:e16703
- Dickinson BD, Altman RD, Nielsen NH, Sterling ML. (2001). Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol 98:853–60
- Einolf HJ, Chen L, Fahmi OA, et al. (2014). Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther 95:179–88
- EMA. (2012). Guideline on the investigation of drug interactions. Pp 21–25. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf
- Fahmi OA, Ripp SL. (2010). Evaluation of models for predicting drug-drug interactions due to induction. Expert Opin Drug Metab Toxicol 6:1399–416
- FDA. (2012). Drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Draft Guidance. Pp 2130. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf
- Grub S, Bryson H, Goggin T, et al. (2001). The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 57:115–21
- Hariparsad N, Carr BA, Evers R, Chu X. (2008). Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36:1046–55
- Le Cluyse EL, Sinz MW, Hewitt N, et al. (2010). Cytochrome P450 induction In: Lu C, Li A, eds. Enzyme inhibition in drug discovery and development. Hoboken, NJ: John Wiley & Sons, Inc, 265–314
- Loos U, Musch E, Jensen JC, et al. (1985). Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin Wochenschr 63:1205–11
- Martin P, Riley R, Back DJ, Owen A. (2008). Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells. Br J Pharmacol 153:805–19
- Siccardi M, Marzolini C, Seden K, et al. (2013). Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet 52:583–92
- Sinz M, Kim S, Zhu Z, et al. (2006). Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375–88
- Smith DA, Dickins M, Fahmi OA, et al. (2007). The time to move cytochrome p450 induction into mainstream pharmacology is long overdue. Drug Metab Dispos 35:697–8
- Yamano K, Yamamoto K, Kotaki H, et al. (1999). Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats. Drug Metab Dispos 27:1225–31
- Yamano K, Yamamoto K, Kotaki H, et al. (2000). Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: implication of concentrative uptake of inhibitors into liver. J Pharmacol Exp Ther 292:1118–26
- Yamashita F, Sasa Y, Yoshida S, et al. (2013). Modeling of rifampicin-induced CYP3A4 activation dynamics for the prediction of clinical drug-drug interactions from in vitro data. PLoS One 8:e70330